Antibody-Drug Conjugates: Manufacturing Challenges and Trends

Antibody-drug conjugates (ADCs), a form of Immuno-conjugate or bio-conjugate, are an emerging class of medicines designed for high-specificity targeting and destruction of cancer cells....
Drugs & Durg Hunters

Drugs and Drug Hunters

All products of the creative process are a reflection of the individual makeup of the inventors.  A painting by Mark Rothko looks like a...

To Reimburse or not to Reimburse – That is the Question

Novel, innovative (bio)pharmaceutical drugs are an important part of our global healthcare system, offering advanced, radical new personalized and targeted therapy options to patients...

Evolving CMC Analytical Techniques for Biopharmaceuticals

1.0 Abstract During the (early) preclinical drug development process as well as manufacturing of biopharmaceutical (protein) products, analysis and characterization are crucial in gaining a...

Outsmarting Cancer – From the War on Cancer to the Cancer Moonshot

On May 25, 1961, President John F. Kennedy announced, before a special joint session of congress, the dramatic and ambitious goal of sending a...

When Data Integrity Takes Center Stage

1.0 Abstract Data integrity has become an important issue. To comply with regulations, companies need to optimize data integrity and the underlying strategies involved in...

How can Single-use Bioprocessing Technologies Tackle Current Bottlenecks?

Traditional systemic administration of chemotherapeutic agents does not differentiate between healthy and diseased tissue. Antibody-drug conjugates (ADCs) are highly efficacious drugs with lower side...

The Challenge of cGMP in the Manufacturing of Antibody-drug Conjugates

1.0 Introduction Antibody-drug Conjugates or ADCs are a new generation of highly hazardous / highly toxic pharmaceutical products used, among other things, in the targeted...

Big Data in Science: Which Business Model is Suitable?

1.0 Abstract The first aim of this paper is to define which Big Data business model (in science-based activity) will be able to provide IT...
Featured Image: Lonza, Visp, Switzerland. Courtesy: © 2010 - 2018 Lonza, Visp, Switzerland. Used with permission.

New Learning Makes ADC Development Less Empirical

A few decades ago, the pharmaceutical industry developed and commercialized racemic small molecule drugs. Despite the success achieved with racemic drugs, the risk associated...